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plus 60Gy with 3DCRT). In 2012, a new relapse was operated on subtotal surgery to avoid sensitive aphasia (as seen on post-
surgery MRI) We compared a total dose treatment of 36Gy, delivered in 20 sessions of 1.8Gy per fraction with 3DCRT, IMRT and
RapidArc®.
Results. 3DCRT: V95: 91%/V100:61% D95: 33.6Gy/D100: 28.8Gy/Brainstem: Dmaximum: 35Gy, Dmedian: 18Gy Visual pathways:
Dmaximum: 28.2Gy, Dmedian: 19Gy IMRT: V95: 99.97%/V100: 91.05% D95: 35.65%/D100: 33.67%/Brainstem: Dmaximum: 35.07%,
Dmedia: 19.91GyVisual pathway:Dmaximum: 13.72Gy/Dmedian: 11.3GyRAPIDARC:V95: 99.98%/V100: 91.8%D95: 35.42Gy/D100:
33.16Gy/Brainstem: Dmaximum: 36.13Gy, Dmedian: 17.4Gy Visual pathway: Dmaximum: 12.7Gy/Dmedian: 10.13Gy.
Conclusions. We conclude that the three techniques analysed can achieve good cobertures of PTV, sparing the different OARs and
eloquent areas.
http://dx.doi.org/10.1016/j.rpor.2013.03.133
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Introduction. The high degree glial tumors account for 2% of neoplasms in accident. They are aggressive tumors that require
multidisciplinary approach with surgery, radiotherapy and chemotherapy.
Objective. Analyzed, in a retrospective series of malignant glial tumors, treatments performed, results and acute and chronic
morbidity resulting therefrom.
Material and methods. Between February 2008 and February 2012 we evaluated 109 patients with primary CNS malignancies (54%
male and 46% female) with a median age of 61 years. Glioblastoma Multiforme were 82%, 11% Anaplastic Astrocytoma, 3%
Anaplastic Oligoastrocytoma, 4% Anaplastic oligodendroglioma and 6% histological conﬁrmation could not be obtained so it was
based on imaging test. 94% of patients were operated: 28% by total resection, 47% by partial resection and 19% exclusive biopsy.
97% of patients received adjuvant treatment: 84% RT+QT (Stupp scheme), 8% exclusive RT, 6% RT+QT in clinical trial and 3%
none. In 97% of patients we planned 3D CRT and in 3% Fractionated Stereotactic Radiotherapy. Median radical treatment dose
was 60Gy and 35Gy in palliative treatments.
Results. Median follow-up was 252 days. Toxicity assessed by CTCAE v4.0: of the 97 patients who received adjuvant treatment
with QT, 19% had thrombocytopenia≥grade II and 24%≥grade II leukopenia. 97% of them showed no memory impairment and
94% had no cognitive impairment. The surgical site failure occurred in 88% of patients, the remote failure occurred in 9% of
patients and 3% in both.
Conclusions. The high-grade glial tumors are tumors of poor prognosis with short survival being achieved discreetly extend thanks
to the combination of treatments.
http://dx.doi.org/10.1016/j.rpor.2013.03.134
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Purpose. To evaluate the survival of patients with newly diagnosed Glioblastoma Multiforme depending on the surgery performed.
Materials and methods. From April 2002 till January 2012, 82 patients (43 male and 39 female) mean age 63.3 (range from 29
to 82) with newly diagnosed Glioblastoma Multiforme was treated in our hospital. The treatment protocol consisted of total
surgery, partial surgery or biopsy only followed by external radiation therapy (6000 cGy in 30 fractions with conformal radio-
therapy technique) and concurrent chemotherapy with Temozolomide (75mg/m2/day) and adjuvant Temozolomide (TMZ)
monotherapy for 6 cycles (150–200mg/m2/5days). The median survival was evaluated depending on the type of surgery per-
formed. Total surgery was realized in twenty-nine patients (35.4%), ten patients (12.2%) were treated by partial surgery and
biopsy only was made in forty-three patients (52.2%). Survival was calculated using Kaplan–Meier and Long Rank (Mantel Cox)
methods.
Results. Overall survival for our patients was 14.5 months. Two patients who were diagnosed on April 2006 and December 2010
having undergone biopsy and total surgery respectively are still alive. Twenty-eight patientswere treated by total surgery followed
by concurrent chemotherapy–radiotherapy (QTRT) with TMZ and adjuvant TMZ with a median survival of 18 months. Partial
surgery followed by concurrent QTRT and adjuvant TMZ was realized in 10 patients with a median survival of 19.9 months.
Forty-two patients were not treated by surgery and received treatment which consisted of concurrent QTRT and adjuvant TMZ
with a median survival of 10.8 months. The longer survival was 68 months in a patient who was treated by total surgery followed
by concurrent QTRT and adjuvant TMZ. According to the Long Rank method a signiﬁcant median survival difference is observed
between biopsy and partial surgery with a p=0.016 and Biopsy and total surgery also, with a p=0.004. There is no difference
between total and partial surgery with a p=0.861.
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Conclusion. Our results correlate with published data and show an overall survival around 14 months in those patients who are
treated by concurrent QTRT and adjuvant TMZ. Our results also demonstrate surgery as a prognostic factor with a longer median
survival.
http://dx.doi.org/10.1016/j.rpor.2013.03.135
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Introduction. Ependymomas are glial tumors and represent 7–11% of all primary spinal tumors. The mean age at presentation is
30–39 years.Myxopapillary ependymomas arewell differentiated low-grade tumors that typically occur in the lumbosacral region.
They progress slowly and cause neurologic deﬁcits for their size and they have tendency to spread throughout the neuraxis. In
cases with subtotal resection followed by EBRT, OS at 10 years is 67–100%.
Objective: To report a case of myxopapillary ependymoma and its multidisciplinary treatment.
Case report. We describe a case of myxopapillary ependymoma in a 28 year-old male that was presented with sciatic pain in
both lower extremities of 3 years duration, in the last month presents progressive loss of strength with difﬁculty walking and
diuresis. Magnetic resonance imaging (MRI) showed a lesion in horse-tail. By the lesion localization the patient was underwent
to a subtotal resection with symptomatic resolution after the procedure. Histologically was a myxopapillary ependymoma, the
cells were immunoreactive for GFAP(+++), S-100(+), EMA(+/−). The CNS CT scan was normal. The post-surgery MRI revealed a
residual tumor. The neuro-oncology group decided to give local radiation of 45Gy/1.8Gy.
Results. The MRI revealed no recurrence tumor at the present, in the follow-up of the last 24 months.
Discussion. Myxopapillary ependymomas are the most common spinal cord tumor in the conus – ﬁlum terminale region. They are
well circumscribed in the MRI and usually enhance brightly with contrast material. Surgical resection is the treatment of choice.
If the tumor is adjacent to the conus, resection is more difﬁcult and more likely to result in signiﬁcant neurologic sequelae with
macroscopic residual tumor. Postoperative radiotherapy in subtotal resected tumors or with craniospinal axis dissemination is
associated with better local control rates without late radiation damage to the spinal cord.
http://dx.doi.org/10.1016/j.rpor.2013.03.136
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Introduction. Technological development and improved cancer treatments are associated with increased survival of patients with
cancer. However, there is little literature on deﬁcits and symptoms and limit their quality of life in patients with brain metastases.
Objectives. It determinates a neuropsychological performance and cognitive symptoms of patients with brain metastases who
received radiation treatment. Besides it evaluates the quality of life after this treatment.
Methods. This study was conducted in Group IMO Foundation (Madrid Institute of Oncology). We analyzed 10 patients diagnosed
brain metastases (lung and breast carcinomas). All patients were treated with radiotherapy for brain injury: radiosurgery and/or
whole brain radiotherapy. The assessment procedure was: (a) ad hoc semistructured interview; (b) quality of life questionnaire
withneurotoxicitymodule; (c) anxiety and clinical depressionquestionnaire, and (d) neuropsychological battery: attention, verbal
memory, perceptual organization, verbal and semantic ﬂuency name and executive functions (phonological ﬂuency, interference,
planning and organization, working memory). Analysis: It will be a descriptive analysis of the characteristics of the population-
level sociodemographic and clinical. It will compare the scores on neuropsychological tests by nonparametric measures (Kruskal
Wallis). Also, it will apply a correlation analysis between quality of life and cognitive functions.
Conclusions. Neuropsychological assessment of this population provides a description of the consequences of the disease and its
treatments. This information should be considered in making treatment decisions by patients and professionals. It also helps
the planning objectives of rehabilitation programs that improve the quality of life and to identify prognostic factors.
http://dx.doi.org/10.1016/j.rpor.2013.03.137
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Introduction. Optic pathway tumors (OPT) are rare and are often associated with type I neuroﬁbromatosis. Optic pathway gliomas
account for 65% of all OPT’s. They are often diagnosed by MRI without biopsy.
Objective. Treatment with RTE of paediatric brain tumor without prior histology.
